ALNYLAM PHARMACEUTICALS, INC. 10-K filing
Filed 2026-02-12 · Report date 2025-12-31 · 2025 FY
Filing metadata
- Accession number
- 0001628280-26-007497
- Form type
- 10-K
- CIK
- 0001178670
- Primary document
- https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for ALNYLAM PHARMACEUTICALS, INC..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $3.7B | - | - |
| Cost Of Revenue | $677.2M | - | - |
| Operating Income | $501.6M | - | - |
| Net Income | $313.7M | - | - |
| Eps Basic | 2.39 | - | - |
| Eps Diluted | 2.33 | - | - |
| Cash And Equivalents | $1.7B | - | - |
| Total Assets | $5.0B | - | - |
| Total Liabilities | $4.2B | - | - |
| Shareholders Equity | $789.2M | - | - |
| Operating Cash Flow | $524.1M | - | - |
| Capital Expenditures | $58.7M | - | - |